Susceptibility testing is performed by a broth microdilution method that includes: Amikacin, Ciprofloxacin, Clarithromycin, Ethambutol, Ethionamide, Isoniazid, Linezolid, Moxifloxacin, Rifampin, Rifabutin, Streptomycin. Clarithromycin is the only antimicrobial for which CLSI interpretive guidelines are established.

Identification of the isolate is required.

Linezolid and moxifloxacin will be tested with results released only for isolates non-susceptible to clarithromycin.

*This test was performed using a kit that has not been cleared or approved by the FDA. The analytical performance characteristics of this test have been determined by Focus Diagnostics. This test should not be used for diagnosis without confirmation by other medically established means.

This test is available for New York patient testing.